Rotman, Yaron
Sanyal, Arun J
Clinical trials referenced in this document:
Documents that mention this clinical trial
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
https://doi.org/10.1136/gutjnl-2019-319104
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431
Documents that mention this clinical trial
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
https://doi.org/10.1136/gutjnl-2019-319104
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431
Documents that mention this clinical trial
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431
Documents that mention this clinical trial
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
https://doi.org/10.1136/gutjnl-2019-319104
Management of non-alcoholic fatty liver disease
https://doi.org/10.1136/bmj.m4747
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431
Documents that mention this clinical trial
Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges
https://doi.org/10.1136/gutjnl-2019-319104
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431
Documents that mention this clinical trial
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431
Documents that mention this clinical trial
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431
Documents that mention this clinical trial
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431
Documents that mention this clinical trial
Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation
https://doi.org/10.1136/gutjnl-2017-315691
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431
Documents that mention this clinical trial
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431
Documents that mention this clinical trial
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431
Documents that mention this clinical trial
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431
Documents that mention this clinical trial
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431
Documents that mention this clinical trial
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis
https://doi.org/10.1136/gutjnl-2022-327777
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431
Documents that mention this clinical trial
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis
https://doi.org/10.1136/gutjnl-2022-327777
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431
Documents that mention this clinical trial
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
https://doi.org/10.1136/jitc-2021-002371
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431
Documents that mention this clinical trial
Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation
https://doi.org/10.1136/gutjnl-2017-315691
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
https://doi.org/10.1136/gutjnl-2016-312431